MoneyWorks4Me

Lupin informs about press release

17 Jun 2021 Evaluate

Lupin has informed that it has enclosed is a Press Release on 17th June 2021 as regards receipt of USFDA approval for the Company’s Sevelamer Hydrochloride Tablets, 400 mg and 800 mg to market a generic equivalent of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..